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The objective of this study was to find the earliest time at
which it was possible to detect clinical pregnancy in an in-
vitro fertilization (IVF) treatment cycle supported with
human chorionic gonadotrophin (HCG), and also retro-
spectively to diagnose abnormal ovarian- or endometrium-
related situations in failure cycles. Serum samples were
taken in 41 IVF cycles at frequent intervals from the
beginning of ovarian stimulation until menstrual bleeding
occurred or a pregnancy was established. Concentrations
of oestradiol, progesterone, placental protein 14 (PP14),
pregnancy-specific pi-glycoprotein (SPj), and pregnancy-
associated plasma protein A (PAPP-A) were determined in
the serum samples using commercially available (steroid)
or purpose-developed (protein) immunoassays. The cycles
were retrospectively distributed into four outcome groups:
(i) fertilization failure (FF, n = 8); (ii) implantation failure
(IF, n = 10); (iii) 'interaction' (embryo-endometrium) cycle
(IC, n = 14), and (iv) clinical pregnancy (CP, n = 9). The
embryo-endometrium interaction was detected by a rise
in SP! in 23 cycles (70% of embryo transfers) at a time
when endogenous HCG was still masked by external sup-
port. Early ('false') positive SP] concentrations were
observed in two out of eight and five out of 14 cases in
groups FF and IC respectively, but never amongst the
ongoing pregnancies (CP). PAPP-A did not distinguish
pregnancy from the other outcomes. The PP14/progesterone
ratio was lower, later in the cycle, in CP than in the other
groups. We conclude that, while it is not possible to predict
the outcome of a given IVF cycle earlier than 2 weeks after
embryo transfer, the hormonal patterns can be used to
detect abnormalities (e.g. endometrial asynchrony) which
may be useful for subsequent treatment cycles in the
same patient.
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Introduction
In order to organize treatment by in-vitro fertilization (IVF)
and embryo transfer with least strain on patients and staff, it
would be an advantage to know the outcome, be it positive or
negative, of a given cycle as early as possible. In addition,
there are various reasons for failure to establish an ongoing
pregnancy: ovarian- or endometrium-related situations could
be responsible as well as an impairment of the dialogue
between maternal tissues and the embryo; the importance of
synchrony, or rather the maximal allowed extent of deviation
from it, between endometrium and embryo also requires
assessment. At early stages such as during the first 3 weeks
after embryo transfer, these objectives can only be met by
biochemical investigation.
Amongst the described pregnancy-specific proteins, human
chorionic gonadotrophin (HCG) is the first to be produced and
released by the embryo, and pregnancy is usually detected
by measurement of this hormone in the maternal serum;
concentrations >40 mlU/ml would theoretically occur from
day 13 after embryo transfer. The administration of exogenous
HCG during luteal phase support, however, masks the embryo-
derived fraction of this hormone in the mother's serum during
this period (i.e. days 12-15 after embryo transfer). A typical
serum HCG concentration would be 40-60 mlU/ml 24 h after
an injection of 1000 IU of HCG. We therefore decided to test
the usefulness of a very sensitive enzyme-linked immuno-
sorbent assay (ELISA) for a pregnancy-specific pi-glyco-
protein (SP,) which, like HCG, is produced by the trophoblast
but which is biochemically unrelated to it. SP, can only be
detected in the serum from -day 18 or 20 after embryo transfer
by commercial enzyme or radioimmunoassay respectively. The
more sensitive enzyme assay developed by Grenner (1978)
has now been withdrawn from the market. With the aim of
testing the usefulness of SP) for reliable diagnosis of early
pregnancy in the presence of exogenous HCG, we have
developed a highly sensitive (0.02 ng/ml) microplate enzyme
immunoassay for this protein.
In this context, we also studied the possible reasons for
failure in those cycles not leading to pregnancy; we considered
whether SP, and pregnancy-associated plasma protein A
(PAPP-A), a large glycoprotein normally produced in preg-
nancy by the trophoblast but for which ectopic production had
been demonstrated (Schindler et al., 1984), would show distinct
serum concentration patterns according to outcome. Another,
probably better candidate for such diagnosis is endometrial
placental protein 14 (PP14 or a2-PEG) which is a major
secretory product of the endometrium in the late luteal phase
(Belle/ al, 1986) and whose production is positively correlated
with that of progesterone (Bell and Drife, 1986). However,
this relationship is a complex one with at least one unknown
factor in between, which is illustrated by several observations:
(i) there is a time delay of several days; (ii) serum PPM is
strongly reduced in pregnancies resulting from ovum donation
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(Johnson et al., 1993); and (iii) in contrast to prolactin, it is not
possible to stimulate PP14 production in vitro by endometrial
explants exposed to progesterone (Bersinger et al., 1995b).
PPM is also produced by the Fallopian tubes (Maguiness et al.,
1993) and serous ovarian cysts (Riitinen, 1992). Moreover, it
can be detected in the serum of women who have undergone
hysterectomy (Seppala et al., 1987; plus our own unpublished
observations). In ovarian stimulation and its associated high
steroid concentrations, the factors influencing the release
patterns of PP14 and other secretory products are likely to be
altered. In this study, we assessed serum PP14 in relation to
progesterone concentration using the PP14/progesterone ratio
in four groups of patients (see below). We found that this
ratio, from around the time of implantation, was lower in the
group of patients with ongoing pregnancies than in the others,
which indicates that in the implantation failure and 'interaction'
cycles (an early form of biochemical pregnancy), the endo-
metrial PPM response was too fast to match the developmental
stage of the embryo (asynchrony).
Materials and methods
Patients and in-vitro fertilization protocols
A total of 37 patients (mean age 32.1, range 25—40 years) provided
41 cycles leading to oocyte retrieval and inclusion in this study.
Ovarian stimulation was performed according to an identical protocol
in all of them: 0.1 mg s.c. per day of gonadotrophin-releasing hormone
(GnRH) agonist (Decapeptyl; Ferring, Dubendorf, Switzerland) start-
ing from the mid-luteal phase of the preceding cycle ('long' protocol)
until the day of HCG administration (day of oocyte retrieval -2),
human menopausal gonadotrophin (HMG, Pergonal; Serono, Zug,
Switzerland) 150-300 IU/day for 9-12 days, and 10 000 IU of HCG
(Profasi; Serono) to induce ovulation. Assessment of functional
follicular maturation was by ultrasound examination (by the same
clinician, A.W.B., in all patients) together with serum oestradiol
measurement. Transvaginal oocyte retrieval was performed under
light sedation and transvaginal ultrasound guidance 34-38 h after
HCG administration. The heparin-containing flushing medium used
was obtained from Medi-Cult, Copenhagen, Denmark. The oocytes
were cultured in IVF medium (Medi-Cult), inseminated with 50 000-
100 000 motile spermatozoa prepared by either Percoll gradient or
swim-up in the same medium. The culture medium was replaced the
following day after microscopic assessment of fertilization. Two or
three embryos were transferred 2 days after oocyte retrieval. Luteal
support was given by injecting 1000 IU of HCG on the day of
embryo transfer and every second day thereafter, until a clinical
pregnancy was established or a menstrual period occurred. A serum
sample was collected from each patient on the following days, with
exceptions due to patient availability: first day of HMG stimulation,
-1 week later, on HCG day (day of oocyte retrieval -2), oocyte
retrieval day, embryo transfer day (day of oocyte retrieval+2), day
of oocyte retrieval-!-11 ( ± 2 ) days, day of oocyte retrieval+18 (± 2)
days. Oestradiol was determined immediately by routine laboratory
procedure, and progesterone, endometrial PPM, SP|, and PAPP-A
were assayed at the end of the cycle in batches as described later.
The patients were assigned to one of four groups retrospectively,
according to outcome: (i) fertilization failure (FF, no transfer), n =
8; (ii) implantation failure (IF), i.e. no SP] rise at any time after day
of embryo transfer+12, n = 10; (iii) 'interaction cycle' (IC),
i.e. SP) rise between day of embryo transfer+12 and day of
embryo transfer+17, n = 14; (iv) clinical ongoing pregnancy (CP),
n = 9. No case of 'biochemical pregnancy' (i.e. an HCG value
>1000 mlU/ml without ongoing pregnancy) was encountered.
Immunoassays of hormones and marker proteins
Oestradiol was determined immediately after receipt of the serum,
by lanthanide immunofluorometric assay (Delfia; Wallac, Turku,
Finland) according to the manufacturer's instructions. Progesterone
was measured by radioimmunoassay using a coated tube kit
(Coat-a-count; DPC, Los Angeles, CA, USA). The sample volume
was 100 ul; and for sera obtained between oocyte retrieval and day
of oocyte retrieval +11 inclusive (day of oocyte retrieval +18 in some
cases, which included the whole CP group) a 1:10 dilution was made
with zero standard prior to assay. Intact dimeric HCG was determined
from day 13 after oocyte retrieval by Delfia methodology (Wallac).
ELISAs, developed in our laboratory, were used to assay PP14,
SP), and PAPP-A as follows: PP14 was determined in a sandwich
procedure with different antibodies for immobilization and detection.
Microtitre plate strips (Maxisorp F16; Nunc, Roskilde, Denmark)
were coated with an immunoglobulin (Ig) G preparation of a polyclonal
rabbit antibody, raised against PP14 purified from early pregnancy
(13 weeks maximum) amniotic fluid, at a concentration of 10 Ug/ml
in sodium carbonate buffer (50 mM, pH 9.6, overnight at 4°C).
The reaction volume was 100 ul/well. Excess sites were blocked
with bovine serum albumin (BSA; Fluka, Buchs, Switzerland) at
5 mg/ml in phosphate-buffered saline (PBS) at pH 7.4 for at least
2 h at room temperature. Patient sera were diluted 1:2 with assay
buffer (AB), i.e. PBS containing BSA (Fluka, 20 mg/ml) and non-
ionic detergent (Emulsit, Daiichi, Kogyo, Japan, 0.05% v/v). After a
90 min incubation at 37°C the plate was washed with PBS containing
Tween-20 (PBST, Surfact-Amps; Pierce, Rockford, IL, USA). Then
monoclonal anti-PP14 prepared by Riitinen et al. (1991) and kindly
supplied by Dr M.Seppala, University of Helsinki, Finland, was added
at a dilution of 1:10 000 in AB, and the plate incubated for a further
60 min at 37°C. After another washing step, peroxidase-conjugated
goat anti-mouse IgG (ELISA grade, Bio-Rad, Hercules, CA, USA,
dilution 1:3000 in AB) was added and the plate incubated again as
before. After extensive washing the amount of bound enzyme was
determined with perborate (0.03%) as a substrate and ort/io-phenylene-
diamine (0.8 mg/ml) as a chromogen (both from Sigma, St Louis,
USA) in a citrate/phosphate buffer (100 mM, pH 5.0). Using this
protocol, the inherent high specificity of the monoclonal antibody
was combined with high assay sensitivity (0.02 ng/ml).
A two-step sandwich ELISA procedure was used to determine SP|
in an assay volume of 200 ul/well. Maxisorp plates were coated
with rabbit polyclonal anti-SP| IgG (Dako, Glostrup, Denmark) at
10 ug/ml and post-coated with BSA as above (see PP14). Patient
serum was diluted 1:2 in AB (the same as for PP14), added to the
wells and incubated for 90 min at 37°C. After washing the plate with
PBST, the enzyme conjugate (HRP-anti-SP), prepared with the two-
step glutaraldehyde method and obtained from Dako (but now
discontinued) was added at 0.5 (Xg IgG/ml in AB and the plate
incubated another 60 min at 37°C. Subsequent washing and develop-
ment of peroxidase with o/f/io-phenylene-diamine (200 (0.1/well) was
as described for PP14. Under these conditions, the sensitivity of the
SP| assay was a final 0.02 ng/ml which, at the minimum serum
dilution used here, resulted in a practical sensitivity of 0.04 ng/ml.
Calibration was done using commercial standards ('Enzygnost-SP|')
obtained from Behringwerke (Marburg, Germany).
The ELISA method used for the determination of PAPP-A has
been described previously (Bersinger et al., 1995a). A buffer system
different from that in SP( and PP14 assays was used for reasons of
lower background and resulting increased sensitivity. Briefly, Maxi-
sorp microplate strips were coated with polyclonal rabbit anti-PAPP-
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Figure 1. Detection of implantation by serum pregnancy-specific
P1-glycoprotein (SPi ) and human chorionic gonadotrophin (HCG).
Individual readings obtained between the day of oocyte
retrieval+13 and the day of oocyte retrieval+19 for 'interaction'
group (IC; no ongoing pregnancy, open circles) and clinical
pregnancy group (CP; filled circles). Two patients assayed twice are
shown by pairs of points joined by solid lines.
A IgG, obtained from Dako but absorbed prior to use in ELISA, over
an immobilized fraction of pregnancy serum filtrate <300 000 kDa
to remove anti-SPj and other contaminating activities directed at
pregnancy serum constituents of lower molecular weight. After
coating with 2 (ig IgG/ml at pH 9.6 and blocking of the excess sites
with BSA (Fluka) at 5 mg/ml in PBS, the assay was run in PBS
containing 0.5% non-fat milk proteins ('Blotto', obtained from Pierce).
The same buffer was used for the second incubation with peroxidase-
antibody conjugate which was also obtained from Dako and used
without prior treatment at a 1:500 dilution. Assay sensitivity was
0.0036 mlU/ml [World Health Organization (WHO) reference prepara-
tion 78/610 = 100 mlU/ml)], intra- and interassay coefficients of
variation were 4.3 and 10.2% respectively.
Results
Detection of pregnancy
We were unable to distinguish the clinical pregnancies from
the outcome groups IF and IC, prior to day 15 after oocyte
retrieval, by single serum determination of PP14, SP|, or
PAPP-A. In 23 out of the 33 cycles with embryo transfer
(70%), SPj was positive on at least one occasion on or after
the day of oocyte retrieval+13. Figure 1 shows that these
values were between one and two orders of magnitude above
the assay sensitivity and that SPb at this stage, did not
distinguish between ongoing pregnancies and the IC group.
HCG, on the other hand, tended to be higher with advancing
time in the CP group but it could not be used as an early
discriminator because of the exogenous hormone given for
luteal support. PAPP-A, structurally different from HCG and
SP| but also primarily of trophoblastic origin, could not be
used to detect pregnancies even on the day of oocyte
retrieval+24. Figure 2 shows individual PAPP-A patterns and
illustrates patient-to-patient variation irrespective of cycle stage
or outcome.
Abnormal SPi patterns
Figure 3 shows the range of SP! patterns obtained in the nine
CP patients as a function of time. The dashed lines represent
the 'abnormal' SP! curves found in six out of the 14 IC group
7 14 21 - 7 0 7
DAYS FROM OOCYTE RECOVERY
21
Figure 2. Senim pregnancy-associated plasma protein A (PAPP-A)
in individual cycles. Left panel, fertilization failures (FF; dotted
lines), implantation failures (IF; dashed lines), and positive
implantation (by SP|) cycles (solid lines) in individual patients
shown by various symbols. Right panel, clinical pregnancies (CP).
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Figure 3. Individual serum pregnancy-specific pi-glycoprotein
(SP|) patterns in clinical pregnancies (CP, solid lines) and in six
cases out of the 14 'interaction cycles' (IC) with abnormal SP[
concentrations on or before embryo transfer (dashed lines). In the
remaining IC cycles, SP| patterns followed those in the CP cycles
until the day of oocyte retrieval+14 to 17, then the SP) values fell
to below assay sensitivity.
cycles with positive SP) after the day of oocyte retrieval+13
but without ongoing pregnancy (the remaining IC group
cycles had undetectable SP] until around the day of oocyte
retrieval+11, when they started to rise like the CP group but
by the day of oocyte retrieval+18 they were declining). No
'abnormal' SP, pattern was observed in the nine cycles where
clinical pregnancy occurred. Moreover, they were never seen
in the IF group, i.e. SPi was never positive before the day of
oocyte retrieval+2 without being positive at least once after
the day of oocyte retrieval+13. Commercially available radio-
immunoassays for SP, would not have yielded a positive result
in any of the six above-mentioned abnormal patterns, and the
pregnancies would only have been detected between day 19
and 24 after oocyte retrieval, i.e. when HCG concentration
would anyway have been increased in spite of exogenous
support.
Steroid hormones
Oestradiol followed a constant pattern according to the response
to ovarian stimulation (data not shown). Progesterone concen-
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Figure 4. Mean + SD of serum progesterone concentrations in the
four outcome groups (fertilization failure, FF; implantation failure,
IF; interaction cycle, IC; and clinical pregnancy, CP) on four
selected days around oocyte retrieval. OPU = day of oocyte
retrieval.
trations 3 and 2 days before oocyte retrieval, on the retrieval
day itself as well as on the embryo transfer day (day of oocyte
retrieval+2) are presented on Figure 4 as means plus SD for
each day and outcome group. There were no statistically
significant differences, but the IC group was noticeable because
serum progesterone was three times higher on the day of
oocyte retrieval -2 than one day earlier (day of oocyte
retrieval -3). In the other three groups (importantly, in the
pregnancy group) no such early sharp increase was observed.
PP14 and the implantation window
PP14 consistently increased over several orders of magnitude
during the middle of the luteal phase in all groups examined.
Before oocyte retrieval, there was considerable variation in
PPM since by using the highly sensitive and specific mono-
clonal immunoassay we found that in the majority of cases
PPM, present probably through gestagenic stimulation from
the previous luteal phase, was cleared to below the assay
sensitivity while in others this was not the case. Such non-
disappearance was observed at a higher frequency in the FF
group (five out of eight) than in the others combined (10 out
of 33). The kinetics of the endometrial secretory response
to progestagenic stimulation was assessed by the PP14/
progesterone ratio. Time courses of this ratio are shown in
Figure 5. There was no outcome-related difference between
the four groups in the proliferative phase since PPM depended
largely on the previous cycle (rate of disappearance). In
the luteal phase, however, we observed a consistently less
pronounced increase in PP14/progesterone ratio in the CP
group (Figure 5A and hatched area in Figure 5B) than in the
two other groups, IF and IC (there was no difference between
IF and IC, Figure 5B). Table I shows the medians of all
available measurements at the day of oocyte retrieval+2,
between the days of oocyte retrieval+10 and +12 inclusive,
and between the days of oocyte retrieval+17 and +21 inclu-
sive, for both ongoing pregnancy (CP) and confounded non-
pregnancy (IF+IC) cycles; it illustrates that the observed effect
on the PPM to progesterone ratio was not only due to high
progesterone concentrations observed in pregnancy, but also
to a slow or retarded production of PPM.
Discussion
In this study, firstly we have attempted to characterize better
the running of IVF cycles for staff and patient convenience
by improving implantation and pregnancy detection. Secondly,
retrospective analysis of previous cycles was undertaken with
the aim of refining the diagnosis of failed IVF attempts.
We tried to find a means of detecting a pregnancy in an
IVF cycle in the presence of exogenous HCG, which is often
administered as a luteal phase support. Therefore, we set up a
method for the detection of very low concentrations of SPh
which is biochemically different from HCG. With this sensitive
assay (but probably not with a commercial radioimmunoassay
for SPj) it was possible to diagnose an implantation 1 or 2
days before it would have been detected by the presence of
excess HCG over the exogenous level. However, SP, did not
distinguish between ongoing and biochemical pregnancies at
this stage. The benefit, if any, of SP| determinations over
measurements of HCG for pregnancy detection therefore seems
to be limited to a comparatively short period. Overall estimates
of HCG remain the most reliable method of detecting early
pregnancy especially if it is not used for luteal phase support.
However, the SP] results might help to decide whether or not
luteal support should be continued, and determinations of this
protein are therefore indirectly beneficial.
Another structurally different trophoblast marker, PAPP-A,
showed at the high assay sensitivity of 0.02 WHO mlU/ml
used here, notable patient-to-patient variation, but no preg-
nancy-related increase in serum concentration before 25 days
after oocyte retrieval. Being a very large molecular entity, its
concentration starts to rise later (in natural cycles around the
day of day luteinizing hormone surge+35). Secondly, SP,
could be used, together with progesterone and PPM, for the
retrospective detection of potentially abnormal cycles, but
on condition that the highly sensitive ELISA (and not the
commercial radioimmunoassays) is used. We do not know
what causes the appearance of low-level SP| around the
hypothetical time of fertilization, but we have observed it
before and a biochemical investigation has been undertaken;
it has shown that this 'abnormal' SP| was not different from
the trophoblast derived protein found at high concentrations
in pregnancy serum (Bersinger, 1985). Production of SP, has
not been found in tissues other than the placenta, although
Klopper el al. (1986) have detected it in the seminal fluid. It
was thus included in the group of pregnancy-specific rather
than pregnancy-associated proteins (Chard and Grudzinskas,
1985). PAPP-A, a member of the group of pregnancy-associated
proteins, has been found in decidua (Schindler et al, 1984),
seminal plasma (Klopper et al., 1986) and non-pregnancy
serum (Bischof et al, 1981; Klopper et al, 1985; this study).
Other pregnancy-associated proteins are produced by maternal
tissue under stimulation (such as pregnancy zone protein by
maternal plasma cells reacting to oestrogen). With the increased
sensitivities of immunoassays for all these markers it is likely
that the boundaries between these formerly well-defined groups
will become less well-defined in future. Assays defined by a
high specificity of the antibodies involved will recognize the
'true' antigen even at very low concentration, except if a
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Figure 5. Individual semi-log patterns of the placental protein 14 (PP14) to progesterone ratio in the clinical pregnancy group (A) and in
transfer cycles without ongoing pregnancy (B) in both implantation failure (dashed lines) and 'interaction' (solid lines) cycles. The patterns
for the pregnancy group after the day of oocyte retrieval -3 are superimposed on B as a hatched area. The various symbols indicate the
individual cycles.
Table I. Median concentrations of serum placental protein 14 (PP14)
between ongoing pregnancy and non-pregnancy cycles
Day of cycle relative to day
of oocyte retrieval
+ 2
+ 10/12
+ 17/21
Pregnancy
n
9
8
9
PP14 (ng/ml)
0.31
5.32
17.8
and progesterone at three
Progesterone (nM)
229
864
1085
different times on and after embryo
No pregnancy
n
24
19
24
PP14 (ng/ml)
<0.05
4.20
40.5
transfer: comparison
Progesterone (nM)
159
219
8.6
potentially cross-reacting protein is excessively elevated, which
cannnot be excluded in pathological situations. We assume
that we have measured 'true' SP|, but cannot explain its
presence in some cycles of our population. Current investi-
gation in our laboratory suggests that some patients are more
likely than others to produce abnormal SP| patterns. Low but
significantly positive serum SPi concentrations at any moment
before the day of oocyte retrieval +10 would therefore poten-
tially identify a patient subpopulation with modified bio-
chemical embryo-maternal interaction behaviour and with
reduced chances of achieving a pregnancy. The same patient-
to-patient variation was observed in this study for PAPP-A.
Like SP,, HCG immunoactivity might also be produced at
abnormal cycle times but no measurements were done because
of the presence of high (on oocyte retrieval day) or moderate
(after embryo transfer) concentrations of exogenous hormone.
The results obtained for these analyses indicate that a certain
defined 'ideal' hormonal pattern might have to be followed or
at least approximated. SP, (and maybe PP14) should be as
low as possible by the day of oocyte retrieval. Progesterone
should not rise too early, an observation made earlier (Fanchin
el al., 1993), but a high serum concentration is of course
required subsequently which is again reflected in the lower
PP14/progesterone ratio in the clinical pregnancies. PP14 must
respond to progesterone stimulation but it is important that
this response be controlled and not too fast, i.e. the endo-
metrium must not advance faster than the embryo and be out
of synchrony. A high progesterone reading (without PPM
determination) can be as good a pregnancy predictor as the
PP14/progesterone ratio (progesterone contributes to the ratio
to a larger extent than does PP14), but we think that the
additional information on the dynamic relationship of the two
markers and on the synchrony of the tissues involved is
valuable for further investigations. The end-points might have
to be refined; in three non-pregnant women, progesterone was
still high on the day of oocyte retrieval +16/17 which made the
PP14/progesterone ratio indistinguishable from the pregnancy
group (envelope in Figure 5B) at that stage.
No biochemical pregnancies corresponding to the definition
of one HCG reading >1000 mlU/ml were observed in our
study group, but this could be because we made early diagnostic
measurements (HCG, SP,, day of oocyte retrieval +17). How-
ever, the boundary between such a biochemical pregnancy and
some of our IC cycles is not a sharp one and the three
mentioned cycles may fall in this 'grey zone'. The importance
of embryo-endometrial synchrony also explains the positive
relationship between transferred blastomere numbers and preg-
nancy rates (Huisman et al., 1994).
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It has been observed, in frozen embryo transfer (Silverberg
et al., 1994) as well as in ovum donation (Righini et al, 1994)
cycles, that early increases in progesterone did not have
the above-mentioned deleterious effect on pregnancy rates
encountered in autologous ovarian stimulation. This also points
to a possible controlling factor operating between progesterone
(i.e. the ovary which is less active in ovum recipients and frozen
embryo transfer patients) and PP14 and/or other hormones
affecting endometrial differentiation and embryo implantation.
Thus it is not the (early) progesterone itself which is responsible
for lower pregnancy rates, but both high early progesterone
and low pregnancy rates are the consequences of another
unknown event. PPM reflects a more complicated network of
interactions than just endometrial output; however, there is no
indication as to what role the ectopically produced PP14
might play in the peri-implantation period. Other factors with
endocrine, and probably also paracrine, acting mechanisms are
involved and further studies, including in-vitro experiments
with endometrial explants and embryo conditioned media will
be required. At this stage, we suggest that the establishment
of a cycle pattern with absent or very low pre-embryo transfer
concentrations of PPM and SP1; and a post-embryo transfer
increase in the PP14 to progesterone ratio not exceeding 0.13
log [PPM (ng)/progesterone (nmol)]/day could be the target
to reach (see Figure 5). Further investigations with a large
number of cycles are still required, but we conclude that the
parameters investigated here will be useful for the diagnostic
assessment, particularly in patients with recurrent IVF failure.
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